Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7658954 | 0.89 | HPGD (0.46) | HPGDALDH1A1LMNAKDM4ERCE1 | |
| SCHEMBL7658957 | 0.89 | HPGD (0.46) | HPGDALDH1A1LMNAKDM4ERCE1 | |
| SCHEMBL7658965 | 0.89 | HPGD (0.46) | HPGDALDH1A1LMNAKDM4ERCE1 | |
| SCHEMBL29437612 | 0.88 | ALDH1A1 (0.41) | HPGDALDH1A1LMNAKDM4ERCE1 | |
| SCHEMBL7454598 | 0.88 | HPGD (0.39) | HPGDALDH1A1LMNAKDM4ERCE1 | |
| SCHEMBL30095450 | 0.88 | HPGD (0.39) | HPGDALDH1A1LMNAKDM4ERCE1 | |
| SCHEMBL5257839 | 0.88 | ALDH1A1 (0.41) | HPGDALDH1A1LMNAKDM4ERCE1 | |
| SCHEMBL7455780 | 0.88 | HPGD (0.39) | HPGDALDH1A1LMNAKDM4ERCE1 | |
| SCHEMBL20822602 | 0.88 | HPGD (0.39) | HPGDALDH1A1LMNAKDM4ERCE1 | |
| SCHEMBL5997910 | 0.88 | HPGD (0.39) | HPGDALDH1A1LMNAKDM4ERCE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016193267-A1 | MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAME | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016012333-A1 | PESTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-28 | — | — | WO | disclosed |
| US-8772290-B2 | Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same | Oscotech Inc. (KR) | 2014-07-08 | — | — | US | disclosed |
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | OSCOTEC INC. (KR) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HIF1A, HIF1AN, EGLN3 | HPGD 122/4885ALDH1A1 43/4885HTT 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.